『Eylea HD Approved for RVO and Extended Dosing』のカバーアート

Eylea HD Approved for RVO and Extended Dosing

Eylea HD Approved for RVO and Extended Dosing

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
まだレビューはありません